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Prostate leiomyosarcoma is an extremely rare and highly aggressive neoplasm that accounts for less than 0.1% of primary prostate
malignancies. We present a patient with primary leiomyosarcoma of the prostate and review 54 cases reported in the literature to
discuss the clinical, diagnostic and therapeutic aspects of this uncommon tumor. Median survival was estimated at 17 months
(95% C.I. 20.7–43.7 months) and the 1-, 3-, and 5-year actuarial survival rates were 68%, 34%, and 26%, respectively. The
only factors predictive of long-term survival were negative surgical margins and absence of metastatic disease at presentation.
A multidisciplinary approach is necessary for appropriate management of this dire entity.
Copyright © 2008 Gerasimos P. Vandoros et al. Thisisanopen access article distributedunderthe Creative CommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Prostate leiomyosarcoma is an extremely rare neoplasm
that accounts for less than 0.1% of primary prostate
malignancies [1]. It is the most common primary sarcoma
of the prostate in adults and comprises 38% to 52%
of primary prostatic sarcomas [2]. We present a patient
with primary leiomyosarcoma of the prostate and review
54 cases reported in the literature to discuss the clinical,
diagnostic, and therapeutic aspects of this uncommon
tumor.
2. CASE REPORT
An 80-year-old man presented with frequent micturition,
dysuria, poor urinary stream, and nocturia of approximately
12-month duration. He reported no hematuria or perineal
pain and denied any constitutional symptoms. There was
no family history of genitourinary cancer. He was a heavy
smoker, drank alcohol socially, and reported no exposure
to hazardous chemicals. Rectal examination revealed a ﬁrm
nodular mass, 3 to 4cm in diameter, involving the left lobe
of the prostate and extending to the edge of the gland.
The right prostatic lobe was diﬀusely ﬁrm. There was no
palpable lymphadenopathy, and the rest of his physical
examination was unremarkable. Prostate speciﬁc antigen
(PSA) at presentation was 2.7ng/mL, and his creatinine
was normal. His last PSA, obtained 3 years earlier by his
primary care physician as part of routine annual physical
examination, was the same.
Patient underwent transurethral resection of the prostate
(TURP), and pathology revealed a dominant population of
neoplastic spindle cells intermingled with giant neoplastic
cells and multifocal necrosis that involved almost the
entire tumor (Figures 1(a), 1(b)). Immunohistochemistry
conﬁrmed the diagnosis of leiomyosarcoma of the prostate.
Speciﬁcally, tumor cells expressed smooth muscle actin
(Figure 2(a)), vimentin (Figure 2(b)), and CD44, while they2 Sarcoma
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Figure 1: Leiomyosarcoma composed of a dominant population of neoplastic spindle cells: (a) intermingled with giant neoplastic cells and
multifocal necrosis (b).
(a) (b)
Figure 2: Immunohistochemistry demonstrates that tumor cells express smooth muscle actin (a) and vimentin (b).
exhibited no staining for S-100, cytokeratins, and CD117 (c-
KIT).
Computed tomography (CT) of the abdomen demon-
strated two hypodense liver lesions, and CT scan of the
chest showed multiple pulmonary nodules and mediastinal
and left hilar lymphadenopathy, all considered suspicious
for metastatic disease. CT of the brain and bone scan was
negative for metastatic disease.
Patient denied any intervention and was treated symp-
tomatically. Three months later, he presented with urinary
retention and acute renal failure. A permanent urinary
catheterwasplaced,andapalliativeexternalbeamradiother-
apy was recommended. Patient denied any treatment and
was discharged home with hospice. He died 2 weeks later.
3. RESULTS
The information for the 54 cases included in this review
was compiled using the PubMed and Medline databases for
articles published in the last 20 years until March 1, 2008
(Table 1). The search terms used were prostate, sarcoma,
leiomyosarcoma, and malignancy. Only articles published in
English were considered.
The median age of the 54-patient cohort included in
this review was 63.8 years (ranging from 40 to 80). The
mostcommonpresentingmanifestations(among38patients
for whom clinical data regarding presenting symptoms were
available) included obstructive urinary symptoms in 89.4%
and perineal or rectal pain in 25.6% of the patients. Less
frequent manifestations were burning on ejaculation and
hematuria, both presented as initial symptoms in only 5.2%
of the patients (Table 2). The diagnosis was obtained by
ultrasound-guided transrectal needle biopsy or TURP in
the majority of patients, whereas transperineal biopsy, CT-
guided biopsy, or suprapubic prostatectomy was only rarely
necessary.
A sizeable proportion of patients (23.5%) had metastatic
disease at the time of diagnosis. Lungs were the most
common sites of metastatic disease accounting for 17.6%
of the cases, followed by liver (11.7%), and bone (5.8%)
(Table 2). Only two patients had metastatic disease in the
brain (3.6%). 61.7% of the patients, included in this review,
underwent surgical resection: 35.5% received external beam
radiation therapy, and 41.1% were treated with adjuvant or
neoadjuvant chemotherapy.
Among 55 patients (including our patient), clinical
outcome data were available for 34 patients. Median sur-
vival was 17 months (95% CI 20.7–43.7 months) and the
1-, 3-, and 5-year a ctuarial survival rates were 68%, 34%,
and 26%, respectively. Our analysis in this 34-patient cohort
demonstrated that the only factors predictive of long-term
survival were absent from metastatic disease at presentation
and negative surgical margins (Figures 3(a) and 3(b), resp.).
Speciﬁcally, patients with metastatic disease at presentation
had worse overall survival than those with no metastatic
disease (median survival for 5 months versus 20 months,
resp., P = .018), and patients with microscopic or gross
residual disease after surgery had worse overall survival thanGerasimos P. Vandoros et al. 3
Table 1: 54 cases of primary prostate leiomyosarcoma included in
this review.
Study Year Patients
Dotan et al. [4] 2006 8
Talapatra et al. [7] 2006 1
Sexton et al. [2] 2001 12
Cheville et al. [3] 1995 23
Dundore et al. [5] 1995 5
Russo et al. [6] 1993 1
Ahlering et al. [11] 1988 4
Table 2: Clinical characteristics of patients with prostate
leiomyosarcoma (retrospective review of 55 patients including this
case).
Clinical characteristics Percent of patients++
Presentation
Obstructive symptoms 89.4%
Perineal/rectal pain 25.6%
Hematuria 5.2%
Painful ejaculation 5.2%
Metastatic disease
at presentation
All sites 23.5%
Lung 17.6%
Liver 11.7%
Bone 5.8%
Therapy
Surgery 61.7%
Radiation 35.3%
Chemotherapy 41.1%
Survival
1 year 68%
3 years 34%
5 years 26%
++ Percentage is based on the patients for whom clinical data were available
in each case.
those with microscopically negative margins after surgery
(median survival for 13 months versus 41 months, resp., P
= .008).
4. DISCUSSION
Primary prostate sarcomas arise from nonepithelial mes-
enchymal components of the prostate stroma and account
for less than 0.1% of primary prostate tumors [1].
Leiomyosarcoma is the most common histological type
in adults (38% to 52% of primary prostatic sarcomas),
while rhabdomyosarcoma is the most common in pediatric
patients [1, 2].
Leiomyosarcoma most commonly presents with signs
and symptoms of urinary obstruction (frequency, urgency,
and nocturia), as well as hematuria, perineal and/or rectal
pain, constipation, burning on ejaculation, and constitu-
tional symptoms such as weight loss [2–7]. In the 54-patient
cohort, obstructive urinary symptoms and perineal or rectal
pain were the most common presenting manifestations.
Physical examination reveals nonspeciﬁc enlargement of
the prostate, while serum PSA is typically within normal
limits [2, 3, 7]. Diagnosis is accomplished by ultrasound-
guided transrectal needle biopsy or TURP in most patients
and less commonly by transperineal biopsy, CT-guided
biopsy, or suprapubic prostatectomy [2]. Lesions typically
range between 2 and 31cm and are frequently very inﬁltra-
tive with focal areas of hemorrhage, necrosis, and/or cystic
degeneration [1, 8].
The majority of leiomyosarcomas are high-grade hyper-
cellular lesions composed of intersecting bundles of
eosinophilic spindle-shaped cells with increased mitotic
activity and moderate to severe nuclear atypia [8]. High-
grade leiomyosarcomas typically exhibit prominent necrosis
and cystic degeneration. Low-grade leiomyosarcomas, with
moderate atypia, scattered mitoses, and a focally inﬁltrative
growth pattern around benign prostate glands, are very rare
[8]. Neoplastic cells commonly express vimentin, smooth
muscle actin, and desmin, while cytokeratin expression is
observed only in approximately 25% of the cases [3]. Some
leiomyosarcomas express progesterone receptor, whereas S-
100 and CD117 are negative in all tumors [9]. Cytogenetic
analysis of primary prostatic leiomyosarcomas reveals clonal
chromosomal rearrangements involving chromosomes 2, 3,
9, 11, and 19 [10].
The local extent of prostatic leiomyosarcoma is deter-
mined by CT or MRI scans, which provide clear delineation
of the tumors from surrounding normal tissues and are
important in assessing whether they are surgically resectable.
A signiﬁcant proportion of these neoplasms presents with
metastatic disease. In the 54-patient cohort, lungs were the
most common sites of metastatic spread followed by liver
and bone. In that regard, chest CT constitutes an impor-
tant component of the metastatic evaluation of prostatic
leiomyosarcomas. Since brain metastases are uncommon,
imaging of the brain should not be performed routinely,
unless there is high-clinical suspicion [2, 3].
Multimodality treatment combinations including
surgery, pre- or postoperative radiation therapy, and
neoadjuvant or adjuvant chemotherapy have been used
in the management of leiomyosarcomas of the prostate,
but there are no standard treatment recommendations
[2–4, 7, 11]. Operable tumors are treated with surgery,
which may be followed by radiation therapy and/or adjuvant
chemotherapy, particularly in patients with positive margins
or nodes [11]. Patients with bulky disease may be treated
with neoadjuvant (preoperative) chemotherapy with or
without radiotherapy followed by an attempt for surgical
resection. In patients with inoperable or disseminated
disease, systemic chemotherapy may induce clinical
responses, but these rarely translate into sustained remission
[2, 3, 12]. Patients who develop isolated pulmonary
metastatic disease after complete resection of the primary
tumor may be oﬀered the option of surgical resection, as this
can be sometimes associated with long-term survival [13].
Surgeries with curative intent include radical retropu-
bic prostatectomy, radical cystoprostatectomy, suprapubic
prostatectomy, and pelvic exenteration [2–4, 11]. Vari-
ous chemotherapy regimens have been used in this dis-
ease, but most patients receive anthracycline (doxorubicin
or epirubicin)-based combinations with alkylating agents4 Sarcoma
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Figure 3: (a): patients with metastatic disease at presentation had worse overall survival than those with no metastatic disease (median
survival for 5 months versus 20 months, resp., P = .018). (b): patients with microscopic or gross residual disease after surgery had worse
overall survival than those with microscopically negative margins after surgery (median survival for 13 months versus 41 months, resp.,
P = .008).
(cyclophosphamide, ifosfamide, or dacarbazine) and/or
vinca alkaloids (vinblastine or vincristine) [2, 14–16].
Platinum-based combinations have also been used with
mixed results [2, 17].
The clinical outcome of patients with prostate
leiomyosarcoma is poor. The 17-month median survival
estimated in our retrospective analysis renders prostate
leiomyosarcoma as one of the most aggressive prostate
malignancies, similar to other histologic subtypes of
prostate soft-tissue sarcomas, more aggressive than prostate
adenocarcinoma, albeit somewhat less aggressive than
prostate carcinosarcoma, which is associated with an
actuarial risk of death of 20% within 1 year of diagnosis
and frequent widespread metastases to bones, liver, and
lungs. When compared to other urologic leiomyosarcomas,
prostate leiomyosarcomas are associated with signiﬁcantly
worse survival than renal and bladder leiomyosarcomas
[18, 19]. Our retrospective analysis revealed that the
presence of metastatic disease at presentation and the
presence of positive surgical margins are associated with
adverse outcome. This ﬁnding is in agreement with the
study published by Sexton et al. [2] although their analysis
involvedallprostatesarcomas(allhistologictypesofprostate
sarcomas grouped together) and did not speciﬁcally examine
prostate leiomyosarcomas.
In conclusion, leiomyosarcoma of the prostate is a rare
neoplasm that usually presents with metastatic disease and
typically follows an aggressive course. A multidisciplinary
approach that includes urology, radiation, and medical
oncology consultations should be employed for appropriate
management of this devastating malignancy.
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